Wells Fargo
GANX icon

Wells Fargo’s Gain Therapeutics GANX Stock Holding History

Wells Fargo’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.4K Buy
11,050
+8,400
+317% +$18.3K ﹤0.01% 5747
2025
Q4 		$8.53K Hold
2,650
– – ﹤0.01% 5983
2025
Q3 		$4.69K Hold
2,650
– – ﹤0.01% 6082
2025
Q2 		$4.77K Hold
2,650
– – ﹤0.01% 6099
2025
Q1 		$5.06K Hold
2,650
– – ﹤0.01% 6027
2024
Q4 		$5.72K Hold
2,650
– – ﹤0.01% 6040
2024
Q3 		$4.72K Hold
2,650
– – ﹤0.01% 5924
2024
Q2 		$3.39K Sell
2,650
-1,106
-29% -$2.87K ﹤0.01% 5935
2024
Q1 		$14.2K Buy
3,756
+29
+0.8% +$120 ﹤0.01% 5661
2023
Q4 		$12.2K Buy
3,727
+4
+0.1% +$11 ﹤0.01% 5783
2023
Q3 		$12.2K Buy
3,723
+5
+0.1% +$19 ﹤0.01% 5751
2023
Q2 		$16.7K Buy
3,718
+5
+0.1% +$24 ﹤0.01% 5791
2023
Q1 		$17.9K Buy
3,713
+1
+0% +$4 ﹤0.01% 5677
2022
Q4 		$11.6K Buy
3,712
+1,001
+37% +$3.13K ﹤0.01% 5490
2022
Q3 		$9K Buy
2,711
+36
+1% +$135 ﹤0.01% 5721
2022
Q2 		$10K Buy
2,675
+2
+0.1% +$7 ﹤0.01% 5747
2022
Q1 		$11K Buy
2,673
+2,650
+11,522% +$11.1K ﹤0.01% 6233
2021
Q4 		$0 Hold
23
– – ﹤0.01% 7420
2021
Q3 		$0 Sell
23
-1
-4% -$8 ﹤0.01% 7154
2021
Q2 		$0 Buy
+24
New +$271 ﹤0.01% 7073

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Wells Fargo's GANX Position: Q1 2026 in Review

Wells Fargo increased its Gain Therapeutics (GANX) stake by 317% in Q1 2026, buying an estimated $18.3K and bringing the position to 11,050 shares worth $21.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5747.

Wells Fargo first reported a position in GANX in Q2 2021 and has held it in 20 quarters since. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Wells Fargo held 11,050 shares of Gain Therapeutics worth $21.4K as of Q1 2026.
  • Wells Fargo bought 8,400 Gain Therapeutics shares in Q1 2026, an estimated $18.3K.
  • Gain Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5747 holding.
  • Wells Fargo first reported a position in Gain Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.